PNU-177864

MedChemExpress

Cat. No.:	HY-103406		
CAS No.:	250266-51-4		
Molecular Formula:	C ₁₈ H ₂₁ F ₃ N ₂ O ₃ S		
Molecular Weight:	402.43		
Target:	Dopamine Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

Product Data Sheet

BIOLOGICAL AC				
Description		PNU-177864 is a potent, selective and orally active dopamine D ₃ receptor antagonist. PNU-177864 is structurally consistent with a cationic amphiphilic agent (CAD) and induces phospholipidosis in vivo. PNU-177864 antischizophrenic activity ^{[1][2]} .		
In Vivo	unusual target organs i	PNU-177864 (12.5-200 mg/kg; oral gavage; daily; for 2-4 weeks; Sprague-Dawley rats) treatment induces phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Male and female Sprague-Dawley rats (8-9-week-old) ^[1]		
	Dosage:	12.5 mg/kg, 50 mg/kg (for 2 weeks), or 200 mg/kg; 8 mg/kg, 25 mg/kg, or 80 mg/kg (for 4 weeks)		
	Administration:	Oral gavage; daily; for 2-4 weeks		
	Result:	Induced phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair follicles.		

REFERENCES

[1]. Rudmann DG, et al. Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864. Toxicol Pathol. 2004 May-Jun;32(3):326-32.

[2]. Vonderfecht SL, et al. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol. 2004 May-Jun;32(3):318-25.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

8 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA